Pharmacogenetics: Not Quite Ready for Prime Time?

Topics: Chromosomal Microarray | CYP2C19 | CYP2D6 | Fragile X | Genetic Testing | MTHFR | Pharmacogenomics | Whole Genome Sequencing

CCPR: Welcome, Dr. Besterman. Please tell us who you are and where you work. Dr. Besterman: I’m an adult and child & adolescent psychiatrist at the Rady Children’s Hospital inpatient child and adolescent unit in San Diego, and I’m a clinical investigator at the Rady Children’s Institute for Genomic Medicine studying psychiatric genetics.

Genetic Testing in Depression

Topics: GeneSight | Genetic Testing | Genetics and Psychiatry | Pharmacogenomics | Randomized controlled trial | Research | Research Update

REVIEW OF: Perlis RH et al, Depress Anxiety 2020;37(9):834–841 STUDY TYPE: Randomized controlled trial By tailoring medications to a patient’s genetic profile, pharmacogenomics promises less medication trial and error, fewer side effects, and better overall outcomes. But does knowing a patient’s pharmacogenetic profile really improve treatme

Genetic Testing: What You Need to Know in 2021

Topics: Autism Spectrum Disorder | CYP2C19 | CYP2D6 | GeneSight | Genetic Testing | Genetics and Psychiatry | Laboratory Testing in Psychiatry | Learning & Developmental Disabilities | Pharmacogenomics | Treatment-Resistant Depression | Whole Genome Sequencing

TCPR: Is there a role for genetic testing in clinical practice? Dr. Nurnberger: I think the evidence is growing that there’s a place for this in clinical practice. The meta-analyses of pharmacogenetic tests are actually looking pretty favorable recently, at least for some genes, particularly CYP2D6 and 2C19 (Bousman CA et al, Pharmacogenomics 2019;20